Skip to content

Released Feb 28, 2023, after the close

10-K filed Feb 28, 2023, 59 days after period end · 0000950170-23-005067

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$44.36Mderived+159.9% vs Q4 2021+196.1% vs Q3 2022
Net Income-$56.36MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$64,419,000N/M
Operating Cash Flowderived-$75,389,000N/M
Free Cash Flowderived-$82,066,000N/M
Margins · derived
Operating margin-145.2%+261.3 pt vs Q4 2021
Net margin-127.1%+275.0 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019
Revenue$44.36M$17.07M$15.90M$2.80M
Net Income-$56.36M-$68.62M-$53.11M-$28.30M
EPS Diluted———-$0.37

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR